Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
Rhea-AI Summary
Rani Therapeutics (Nasdaq:RANI) announced that its management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, at 10:00 a.m. ET.
The CEO and CFO will join a fireside chat and 1x1 meetings, with a live and replay webcast available via the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – RANI
In the May 13 session, RANI declined 4.55%, reflecting a moderate negative market reaction. Argus tracked a peak move of +9.2% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Strategic advisor hire | Positive | -6.2% | Appointment of Dr. Sara Kenkare-Mitra as strategic advisor. |
| Mar 26 | Earnings & update | Positive | -24.9% | Q4/FY 2025 results plus Chugai deal and financing update. |
| Mar 25 | Head of strategy hire | Positive | -5.3% | Appointment of Jesper Høiland as Head of Strategy. |
| Mar 19 | Earnings date notice | Positive | -1.7% | Announcement of date and webcast for Q4/FY 2025 results. |
| Jan 28 | Executive promotion | Positive | -2.9% | Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent RANI news, including strategic hires and a major collaboration/financing update, was followed by negative 24h price reactions despite generally positive operational content.
Over the last few months, Rani reported several milestones, including leadership changes, a major Chugai collaboration worth up to $1.085 billion, and an oversubscribed $60.3 million private placement, plus a Phase 1 start for RT‑114. It also announced its Q4 and full-year 2025 results and made multiple senior appointments. Yet the stock saw 24-hour moves from -1.74% to -24.94% after these updates, suggesting prior news often coincided with short-term selling pressure. Today’s conference-participation news comes against that backdrop.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Details below:
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Date: Tuesday, May 19, 2026 at 10:00 am E.T.
Location: NASDAQ, 151 West 42nd Street, (4 Times Square), New York, NY 10036
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford
Format: Fireside Chat and 1x1 Meetings
Interested parties can access the live webcast for this conference from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replay will be available after the conclusion of the presentation.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
